FDA finds black mold and contamination at Chinese factories making compounded GLP-1 drug components
US FDA inspectors documented egregious conditions at two Chinese factories producing key components for compounded semaglutide and tirzepatide drugs, including black mold on equipment, gross contamination on floors, and employees attempting to hide paperwork and dispose of products during inspections.
